Salus Discovery, LLC
Publicly observedMadison, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Madison | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Salus Discovery, LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | YJ6CYLKZ4JL9 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant19 Sept 2025Publicly observed
NIH SBIR/STTR award: Flow Direct: Next Generation Urine LFA for TB Diagnosis in Point-of-Care Settings
USD 999,991.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant19 Sept 2025Publicly observed
NIH SBIR/STTR award: Flow Direct: Next Generation Urine LFA for TB Diagnosis in Point-of-Care Settings
USD 916,195.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant3 Jul 2025Publicly observed
NIH SBIR/STTR award: 3STEP: A swab-seal-read assay for tuberculosis and RIF resistance enabled by autonomous extraction technology
USD 913,705.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant3 Jul 2025Publicly observed
NIH SBIR/STTR award: 3STEP: A swab-seal-read assay for tuberculosis and RIF resistance enabled by autonomous extraction technology
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.